SAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY, on February 11, 2026, with a fireside chat at 10am ET (link here).Oppenheimer 36th Annual Healthcare Life Sciences Conference on Februa ...

SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a press release on January 29th reporting positive topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne. Denifanstat is a once-daily oral sm ...

SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a press release on January 29th reporting positive topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne. Denifanstat is a once-daily oral sm ...

Core Insights - CancerVax, Inc. has appointed Dr. George Kemble as Senior Scientific Advisor to enhance its universal cancer treatment platform that utilizes the immune system to combat cancer [1][6]. Company Overview - CancerVax is a pre-clinical biotech company focused on developing a customizable universal cancer treatment platform that aims to detect, mark, and kill only cancer cells [6]. - The company's innovative approach involves disguising cancer cells to resemble well-immunized common diseases, such as measles or chickenpox, to leverage the body's natural immune response [4][6]. Leadership and Expertise - Dr. George Kemble is a seasoned biotech executive with extensive experience in virology, vaccines, and small molecule biologics, previously serving as Chairman of the Board at Sagimet Biosciences Inc. [2]. - His background includes significant roles at MedImmune, where he led research and development efforts, including the launch of FluMist®, the first major innovation in influenza vaccines in over 60 years [3]. Strategic Vision - Dr. Kemble's appointment is expected to bring valuable insights into translating immunology into effective therapies, aligning with CancerVax's mission to reframe cancer as a target the immune system can recognize and defeat [5].

Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading, driven by corporate updates, clinical milestones, and acquisition speculation [1] Company Updates - China SXT Pharmaceuticals, Inc. (SXTC) saw a 13.6% increase to $1.42, following the announcement of its Strategic Artificial Intelligence Insights Initiative aimed at integrating AI-driven analytics into product planning and market intelligence [2] - Revolution Medicines, Inc. (RVMD) surged 15.1% to $123.65 after reports of Merck's acquisition talks and the FDA granting Breakthrough Therapy Designation to its drug zoldonrasib for treating specific lung cancer patients [3] - KalVista Pharmaceuticals, Inc. (KALV) advanced 14.0% to $18.04 after reporting preliminary unaudited global net product revenue results for Q4 and the full year ended December 31, 2025, along with other operational indicators [4] - Zentalis Pharmaceuticals, Inc. (ZNTL) rose 8.1% to $3.07, likely due to investor reactions to a previous corporate update outlining key milestones for its drug azenosertib [5] - BriaCell Therapeutics Corp. (BCTX) gained 7.3% to $7.81 without new announcements, indicating momentum-driven trading [6] - Sagimet Biosciences Inc. (SGMT) increased 7.7% to $6.00 after announcing plans to present clinical trial results at an upcoming conference, highlighting anti-fibrotic effects observed in patients [7]

Core Viewpoint - Sagimet Biosciences Inc. is advancing its clinical-stage biopharmaceutical development, particularly focusing on the anti-fibrotic effects of its FASN inhibitor, denifanstat, in treating MASH patients [1][3]. Group 1: Clinical Trial and Presentation - Sagimet will present a poster at the 10th Annual MASH-TAG Conference, highlighting significant improvements in fibrosis for F3 MASH patients and biomarker enhancements in qFibrosis stage 4 MASH patients from the Phase 2b FASCINATE-2 trial [1][2]. - The poster presentation is scheduled for January 10, 2026, and will be delivered by Dr. Rohit Loomba from the University of California San Diego [2]. Group 2: Company Overview - Sagimet is focused on developing novel FASN inhibitors to address dysfunctional metabolic and fibrotic pathways, particularly in conditions linked to excessive palmitate production [3]. - Denifanstat has successfully met all primary endpoints in its Phase 2b FASCINATE-2 trial and is also being tested in a Phase 3 trial for moderate-to-severe acne in partnership with a licensee in China [3]. - The company is also developing a second oral FASN inhibitor, TVB-3567, which is currently undergoing a Phase 1 clinical trial [3]. Group 3: MASH Disease Context - MASH is a severe liver disease affecting over 265 million people globally, characterized by fat accumulation in the liver, inflammation, and fibrosis, leading to serious liver-related outcomes [4]. - There are limited approved treatments for non-cirrhotic MASH and none for MASH cirrhosis, highlighting a significant unmet medical need in this area [4].

Group 1 - The article discusses Sagimet Biosciences Inc. (SGMT) and highlights positive data from a China partner regarding Acne Vulgaris, which is expected to bode well for the company's product TVB-3567 [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not contain any stock or derivative positions in the companies mentioned, nor does it plan to initiate any such positions in the near future [3] - Seeking Alpha emphasizes that past performance is not indicative of future results and does not provide specific investment recommendations [4]

Core Insights - Sagimet Biosciences Inc. announced positive results from the Phase 1 pharmacokinetic trial of its combination therapy involving denifanstat and resmetirom, targeting metabolic dysfunction-associated steatohepatitis (MASH) [1][4] Group 1: Trial Details - The Phase 1 PK trial was an open-label, 2-cohort study with 40 healthy adult participants, aimed at evaluating pharmacokinetics, potential drug-drug interactions, and safety [2] - The combination of denifanstat and resmetirom was well-tolerated, with no serious adverse events or clinically significant laboratory results reported [3][7] Group 2: Future Development Plans - Sagimet plans to advance the combination therapy into a Phase 2 proof-of-concept efficacy trial for patients with MASH and F4 fibrosis, pending regulatory consultation [4][5] - The company aims to initiate the Phase 2 study in the second half of 2026, leveraging data from the Phase 1 trial [5][7] Group 3: Product Information - Denifanstat is an oral, once-daily selective FASN inhibitor, while resmetirom is commercially available as Rezdiffra for non-cirrhotic MASH with moderate to advanced fibrosis [5][6] - Preclinical data indicated a synergistic effect of the combination on liver disease markers, showing improved NAS and hepatic collagen content compared to single agents [5][6] Group 4: Market Context - MASH is a severe liver disease affecting over 265 million people globally, characterized by fat accumulation in the liver and associated metabolic changes [8] - There are currently no approved treatments for MASH cirrhosis (F4), highlighting a significant unmet medical need [8]

Core Viewpoint - Sagimet Biosciences has entered into a license agreement with TAPI Technology & API Services to develop a fixed-dose combination product targeting metabolic dysfunction-associated steatohepatitis (MASH) [1][2][4] Group 1: License Agreement Details - The agreement grants Sagimet a global, exclusive license to innovative forms of TAPI's resmetirom active pharmaceutical ingredient (API) for technical evaluation and manufacture [2][7] - Sagimet plans to develop a fixed-dose combination product containing denifanstat and resmetirom, with pending patent applications covering both the FDC and innovative resmetirom forms [2][7] Group 2: Clinical Trials and Development Plans - Sagimet has initiated a Phase 1 pharmacokinetic (PK) trial for the combination of denifanstat and resmetirom, with topline data expected by the end of 2025 [3][7] - If the Phase 1 trial results are positive, Sagimet aims to advance the combination into Phase 2 trials for F4 patients with MASH, estimated to start in the second half of 2026 [3][4] Group 3: Company Statements and Insights - The CEO of Sagimet emphasized the importance of the Phase 1 trial and the potential for a synergistic combination of therapies to improve clinical outcomes for patients with liver cirrhosis [4] - TAPI's CEO expressed excitement about the collaboration, highlighting TAPI's expertise in API development and the high medical need for therapies targeting liver cirrhosis [5] Group 4: Background on MASH - MASH is a severe liver disease affecting over 265 million people globally, characterized by fat accumulation in the liver and associated with inflammation and fibrosis [10] - There are currently no approved treatments for MASH cirrhosis (F4), indicating a significant unmet medical need in this area [10]

Core Insights - Sagimet Biosciences Inc. has granted an exclusive license for denifanstat to Ascletis Pharma Inc. for the treatment of moderate to severe acne in China, following the acceptance of its New Drug Application (NDA) by China's National Medical Products Administration (NMPA) [1][2] - Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor, which has shown positive results in clinical trials for both acne and metabolic dysfunction associated steatohepatitis (MASH) [2][3] Company Overview - Sagimet Biosciences is focused on developing novel FASN inhibitors aimed at addressing dysfunctional metabolic and fibrotic pathways, particularly those linked to the overproduction of palmitate [3] - The company has successfully completed Phase 2b clinical trials for denifanstat in MASH and has partnered with Ascletis for its Phase 3 clinical trials in moderate-to-severe acne, where denifanstat met all primary and secondary endpoints [3] Clinical Development - Denifanstat has been well tolerated in clinical trials, with Ascletis' Phase 3 trial demonstrating success in treating moderate to severe acne vulgaris [2] - Sagimet is also testing a combination of denifanstat and resmetirom in a Phase 1 PK clinical trial, targeting cirrhotic patients with F4-stage MASH, and is developing a second oral FASN inhibitor, TVB-3567, which is currently in Phase 1 trials [3]